Adherence and Effect on Allergy Medication Use in Allergic Rhinoconjunctivitis Patients Treated With House Dust Mite Allergen Immunotherapy—A Nationwide Cohort Study
- 4 January 2026
- journal article
- Published by Wiley in Clinical Otolaryngology
- Vol. 51 (3) , 394-400
Abstract
Introduction: House dust mite (HDM) allergy significantly impacts quality of life. Allergen immunotherapy (AIT), specifically sublingual immunotherapy (SLIT), is an effective treatment for HDM allergy, but adherence to SLIT remains a challenge. This study aimed to evaluate the impact of adherence to SLIT on the use of allergy medications, including antihistamines, nasal corticosteroids, and inhaled corticosteroids (ICS) in a real‐world setting. Methods: We conducted a nationwide cohort study using data from Denmark's comprehensive registries. Patients who initiated HDM SLIT between 2015 and 2020 were included, with follow‐up through 2022. Adherent patients, defined as those obtaining at least 80% of the prescribed Defined Daily Dose ( DDD ) of SLIT , were compared to non‐adherent patients. Medication use was tracked for antihistamines, nasal corticosteroids, and ICS . Statistical analyses, including Probit and generalised linear models, assessed the likelihood of obtaining medications and the quantity dispensed, adjusted for age and sex. Results: Of 950 patients, 456 (48%) were classified as adherent. Adherent patients showed significantly reduced usage of antihistamines ( p < 0.001) and nasal corticosteroids ( p < 0.001) compared to non‐adherent patients. No significant differences were found in ICS use or dosage. Additionally, adherent patients were more likely to have higher education levels and be married or cohabiting. Conclusion: Adherence to SLIT for HDM allergy is associated with reduced use of antihistamines and nasal corticosteroids. These findings emphasise the importance of SLIT adherence in managing HDM allergy and suggest that improving adherence could further reduce medication usage, improving patient outcomes in real‐world settings.Keywords
This publication has 24 references indexed in Scilit:
- Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapyImmunotherapy, 2024
- Geographical and socioeconomic differences in compliance with and access to allergen immunotherapy in Denmark: A nationwide registry-based study – 1998-2016Respiratory Medicine, 2021
- Benefit of SLIT and SCIT for Allergic Rhinitis and AsthmaCurrent Allergy and Asthma Reports, 2016
- Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trialJournal of Allergy and Clinical Immunology, 2016
- Adherence to Sublingual ImmunotherapyCurrent Allergy and Asthma Reports, 2016
- Respiratory allergy caused by house dust mites: What do we really know?Journal of Allergy and Clinical Immunology, 2015
- Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trialJournal of Allergy and Clinical Immunology, 2014
- Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapyJournal of Allergy and Clinical Immunology, 2013
- How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpointJournal of Allergy and Clinical Immunology, 2010
- Dust mite allergens: Ecology and distributionCurrent Allergy and Asthma Reports, 2002